

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**VOLUNTARY ANNOUNCEMENT –
JS125 RECEIVED THE ACCEPTANCE NOTICE FOR
THE INVESTIGATIONAL NEW DRUG APPLICATION**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 9 July 2024.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has received the Acceptance Notice (《受理通知書》) issued by the National Medical Products Administration. The investigational new drug application for WJ47156 tablets (project code: “**JS125**”) has been accepted. Relevant information is as follows:

ABOUT JS125

Drug name: WJ47156 tablets

Application matter: Clinical Trial of Domestic Production Registration of Pharmaceutical Product
Acceptance No.: CXHL2400678, CXHL2400680

Applicant: Shanghai Junshi Biosciences Co., Ltd.*

Review conclusion: It is decided to be accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China (《中華人民共和國行政許可法》).

JS125 is a targeted histone deacetylases (“**HDACs**”) inhibitor, jointly developed by the Company and Wigen Biomedicine Technology (Shanghai) Co., Ltd.* (微境生物醫藥科技(上海)有限公司), and is intended for the treatment of malignant tumors, and belongs to the class of epigenetic modulator drugs. HDACs are involved in the regulation of the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, and their expression is known to be closely associated with the occurrence and development of various malignant tumors. HDACs have multiple subtypes. JS125 can selectively inhibit HDAC1, HDAC2 and HDAC3, and inhibit tumor by inducing cell cycle block, inhibiting angiogenesis, modulating immune response and promoting cancer cell senescence and apoptosis, thereby achieving the purpose of tumor treatment.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress of the project in strict compliance with relevant regulations.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 9 July 2024

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Meng Anming, Dr. Shen Jingkang and Dr. Yang Yue as independent non-executive Directors.

* *For identification purpose only*